PD-1 blockade is associated with an increase in pro-inflammatory cytokine activity, such as increased circulating levels of interferon-gamma (IFNγ) and interleukin-10 (IL-10), which have positive implications for cancer treatment but can increase the risk of secondary irAEs [22]. Here, IFNG is linked to cancer.